| HOME >> BIOLOGY >> TECHNOLOGY |
AURORA, Colo., Nov. 15, 2011 /PRNewswire/ -- In a strategic effort to refocus and strengthen its organization, the Fitzsimons Redevelopment Authority (FRA) has completed a regimen of planning to make adjustments in the direction, roles, responsibilities and allocation of resources going forward. The announcement is made by Denise Brown, FRA Interim Executive Director, who says, "Our first tactic in refocus involves augmenting our board of directors with four of the area's most well-known and successful leaders in the bioscience industry."
Joining the FRA Board are Donald M. Elliman, Jr., Executive Director of the Charles C. Gates Center for Regenerative Medicine and Stem Cell Biology and current Director and former Chair of the Children's Hospital Colorado Board of Directors; William Freytag, PhD, former Chairman and CEO of Myogen, Inc.; James C. T. Linfield, Partner-in-Charge of the Colorado office of Cooley LLP; and David Perez, President and Chief Executive Officer of CaridianBCT, becoming TerumoBCT.
Brown continues, "We're very pleased to welcome our new board members. These leaders are actively involved the bioscience community - locally, nationally and internationally - and maintain those critical relationships with entrepreneurs, companies and research groups required to guide the FRA through its next phase of growth. This is the first time the FRA has had bioscience executives on its board."
Other FRA Board members include: Bruce Benson, President, University of Colorado; Bruce Schroffel, President, University of Colorado Hospital; John Shaw, Principal, McWhinney; Lilly Marks, Vice President for Health Affairs and Executive Vice Chancellor of the Anschutz Medical Campus; Dwight Rider, Principal, Fruend Investments; and Councilwoman Melissa Miller from Aurora who will be joined by two other elected officials to be named by the Aurora City Council.
About Fitzsimons Redevelopment Authority
The FRA directs the c
'/>"/>
| SOURCE Fitzsimons Redevelopment Authority Copyright©2010 PR Newswire. All rights reserved |
Related biology technology :
1. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
2. Orcrist Bio Inc. Files with European Competent Authority for a Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750
3. NeoStem Expands Stem Cell Collection Center Network Into New Jersey Led by Leading Plastic Surgeon and Anti-Aging Authority
4. Orcrist Bio Inc. Receives Approval from European Competent Authority to Initiate its Planned Phase I, Open-label, Single-ascending-dose, Safety Study of HYC750
5. Kansas Bioscience Authority Commits $50 Million to Increase Venture Capital, Accelerate Bioscience Business Growth
6. Quest Diagnostics Increases Share Repurchase Authority By $250 Million
7. Cord Blood America CEO and Co-Founder Matthew Schissler Named Chairman of Biotech Committee for Nevada Development Authority
8. BioNeutral Starts Commercial Deployment of Its Ygiene 206 Sterilant and Ogiene Products Within Port Authority Facilities Using T.U.C.S. Cleaning Services
9. GeneNews rolls out ColonSentry(TM) test in additional Toronto area labs
10. Rice rolls out new nanocars
11. YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |